In accordance with the pleiotropic actions of leptin, emerging studies have evaluated the efficacy of leptin-based and LEPR antagonist therapy as anti-obesity approaches in the setting of both leptin sensitivity and resistance states. The gene discussed is LEPR; the disease is obesity due to melanocortin 4 receptor deficiency.